| Literature DB >> 23997969 |
Ali Naboush1, Firas Farhat, Selim M Nasser, Francois G Kamar.
Abstract
Introduction. Testicular lymphoma is an aggressive disease with a very poor prognosis. Nasal-type natural killer/T-cell lymphoma (NKTCL-N) in particular is very uncommon and has a rapidly progressive, fatal course. Case Report. We report a case of primary NKTCL-N of the testis in a 38-years-old Middle Eastern man. The patient had a history of primary right testicular tumor diagnosed at an outside institution as a seminoma and treated with orchiectomy followed by chemo/radiation. On admission, the patient had an enormous nasal granuloma with blood workup showing pancytopenia and elevated liver function tests due to active hepatitis B infection. CT scan of the sinuses showed a very large soft tissue mass, and PET scan showed splenomegaly with multiple lymph node masses in the pelvis and the chest areas. Bone marrow and nasal tumor biopsies as well as review of the slides from the initial orchiectomy were all in favor of NKTCL-N lymphoma. The patient was treated with CHOD based combination chemotherapy and responded dramatically to the first two cycles but passed away from fulminant hepatitis B infection. Conclusion. Despite all known treatments of NKTCL-N lymphoma of the testes, this disease has a very poor prognosis and invariably follows an aggressive clinical course.Entities:
Year: 2013 PMID: 23997969 PMCID: PMC3753765 DOI: 10.1155/2013/267389
Source DB: PubMed Journal: Case Rep Oncol Med
Figure 1Pictures (a) and (b) showing anterior and lateral views of nasal granuloma from metastatic testicular ENKTCL-N lymphoma. Pictures (c) and (d) showing a CT of the sinuses with and without contrast, respectively, showing the nasal mass. Note: the patient had consented for the use of those pictures in research purposes.
Figure 2Picture (a) showing dense and diffuse polymorphous population of tumor cells consisting of small to medium sized and large cells with irregular nuclei. Picture (b) showing an immunohistochemistry with tumor cells expressing CD56.